Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT: RGX-314 Gene Therapy in Neovascular AMD
jRCT2073240017Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Modality
- Gene Therapies
01
Overview
Phase 3, randomised, single-blind trial of surabgene lomparvovec in exudative macular degeneration (3 arms), sponsored by AbbVie Inc. Primary endpoint: Mean change from baseline in Best Corrected Visual Acuity (BCVA). Started Jun 2024; status: recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2073240017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073240017.